Repligen Corporation (FRA:RGN)

Market Cap	6.48B -25.6%
Revenue (ttm)	603.33M +11.7%
Net Income	1.48M
EPS	0.02
Shares Out	n/a
PE Ratio	4,376.39
Forward PE	70.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	115.40
Previous Close	115.65
Day's Range	115.40 - 115.40
52-Week Range	94.12 - 156.40
Beta	n/a
RSI	35.04
Earnings Date	Feb 24, 2026

About Repligen

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1981
• Employees: 1,778
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RGN

Financial Performance

Financial numbers in USD